was engineered for enhanced secretion of β-Ffase as an efficient biocatalyst. Initial optimization of transcriptional elements increased extracellular enzyme titer by 8.1-fold, but significant intracellular accumulation persisted. Targeted engineering of the secretory pathway, including modulation of endoplasmic reticulum-associated degradation (ERAD) and vesicle trafficking, further improved secretion efficiency. The highest-yielding strain, BA2-2, achieved a 15.2-fold increase in extracellular activity (80.3 ± 5.6 U/mL) and reduced intracellular retention to 12.3% in shake-flask cultures. Application of highly secreted β-Ffase from this strain in a one-pot bioconversion strategy enabled sucrose conversion to 248.9 ± 20.6 g/L kestose with a productivity of 4.08 ± 0.28 g/L/h. Collectively, these results validate a systematic engineering strategy that combines expression optimization with secretory pathway engineering, enabling the development of an efficient microbial platform for industrial kestose production.
Liao et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: